303 related articles for article (PubMed ID: 34521827)
1. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
[TBL] [Abstract][Full Text] [Related]
2. DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma.
Alberge JB; Magrangeas F; Wagner M; Denié S; Guérin-Charbonnel C; Campion L; Attal M; Avet-Loiseau H; Carell T; Moreau P; Minvielle S; Sérandour AA
Clin Epigenetics; 2020 Nov; 12(1):163. PubMed ID: 33138842
[TBL] [Abstract][Full Text] [Related]
3. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
[TBL] [Abstract][Full Text] [Related]
4. Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.
Misiewicz-Krzeminska I; Sarasquete ME; Vicente-Dueñas C; Krzeminski P; Wiktorska K; Corchete LA; Quwaider D; Rojas EA; Corral R; Martín AA; Escalante F; Bárez A; García JL; Sánchez-García I; García-Sanz R; San Miguel JF; Gutiérrez NC
Clin Cancer Res; 2016 Jan; 22(1):207-17. PubMed ID: 26341922
[TBL] [Abstract][Full Text] [Related]
5. Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma.
Jia Y; Zhou J; Tan TK; Chung TH; Wong RWJ; Chooi JY; Lim JSL; Sanda T; Ooi M; De Mel S; Soekojo C; Chen Y; Zhang E; Cai Z; Shen P; Ruan J; Chng WJ
Blood Cancer J; 2021 Feb; 11(2):32. PubMed ID: 33579893
[TBL] [Abstract][Full Text] [Related]
6. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.
Fulciniti M; Lin CY; Samur MK; Lopez MA; Singh I; Lawlor MA; Szalat RE; Ott CJ; Avet-Loiseau H; Anderson KC; Young RA; Bradner JE; Munshi NC
Cell Rep; 2018 Dec; 25(13):3693-3705.e6. PubMed ID: 30590042
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
Gutiérrez NC; Ocio EM; de Las Rivas J; Maiso P; Delgado M; Fermiñán E; Arcos MJ; Sánchez ML; Hernández JM; San Miguel JF
Leukemia; 2007 Mar; 21(3):541-9. PubMed ID: 17252022
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.
Murase T; Ri M; Narita T; Fujii K; Masaki A; Iida S; Inagaki H
Cancer Sci; 2019 Aug; 110(8):2600-2606. PubMed ID: 31218784
[TBL] [Abstract][Full Text] [Related]
9. Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.
Jin Y; Chen K; De Paepe A; Hellqvist E; Krstic AD; Metang L; Gustafsson C; Davis RE; Levy YM; Surapaneni R; Wallblom A; Nahi H; Mansson R; Lin YC
Blood; 2018 May; 131(19):2138-2150. PubMed ID: 29519805
[TBL] [Abstract][Full Text] [Related]
10. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
Tiedemann RE; Mao X; Shi CX; Zhu YX; Palmer SE; Sebag M; Marler R; Chesi M; Fonseca R; Bergsagel PL; Schimmer AD; Stewart AK
J Clin Invest; 2008 May; 118(5):1750-64. PubMed ID: 18431519
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
15. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.
Agnelli L; Forcato M; Ferrari F; Tuana G; Todoerti K; Walker BA; Morgan GJ; Lombardi L; Bicciato S; Neri A
Clin Cancer Res; 2011 Dec; 17(23):7402-12. PubMed ID: 21890453
[TBL] [Abstract][Full Text] [Related]
16. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
17. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
18. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
Brito JL; Walker B; Jenner M; Dickens NJ; Brown NJ; Ross FM; Avramidou A; Irving JA; Gonzalez D; Davies FE; Morgan GJ
Haematologica; 2009 Jan; 94(1):78-86. PubMed ID: 19059936
[TBL] [Abstract][Full Text] [Related]
19. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
[TBL] [Abstract][Full Text] [Related]
20. Early genetic events provide the basis for a clinical classification of multiple myeloma.
Kuehl WM; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
